Healthcare ❯Pharmaceuticals

Rare Diseases

CNS Disorders Orphan Drug Designation Friedreich's Ataxia

Biogen Reports Mixed Q4 Results and Lowers 2025 Outlook

Biogen Acquires HI-Bio for $1.15 Billion to Enhance Immunology Pipeline